# CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation

> **NCT01966367** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Diane George** · enrollment: 37 (actual)

## Conditions studied

- Bone Marrow Failure Syndrome
- Severe Aplastic Anemia
- Severe Congenital Neutropenia
- Amegakaryocytic Thrombocytopenia
- Diamond-Blackfan Anemia
- Schwachman Diamond Syndrome
- Primary Immunodeficiency Syndromes
- Acquired Immunodeficiency Syndromes
- Histiocytic Syndrome
- Familial Hemophagocytic Lymphocytosis
- Lymphohistiocytosis
- Macrophage Activation Syndrome
- Langerhans Cell Histiocytosis (LCH)
- Hemoglobinopathies
- Sickle Cell Disease
- Sickle Cell-beta-thalassemia

## Interventions

- **BIOLOGICAL:** CD34 Stem Cell Selection Therapy

## Key facts

- **NCT ID:** NCT01966367
- **Lead sponsor:** Diane George
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-03
- **Primary completion:** 2030-02
- **Final completion:** 2030-02
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01966367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01966367, "CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01966367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*